1. Home
  2. ATHA vs DSS Comparison

ATHA vs DSS Comparison

Compare ATHA & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • DSS
  • Stock Information
  • Founded
  • ATHA 2011
  • DSS 1984
  • Country
  • ATHA United States
  • DSS United States
  • Employees
  • ATHA N/A
  • DSS N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • DSS Containers/Packaging
  • Sector
  • ATHA Health Care
  • DSS Consumer Discretionary
  • Exchange
  • ATHA Nasdaq
  • DSS Nasdaq
  • Market Cap
  • ATHA 10.6M
  • DSS 8.9M
  • IPO Year
  • ATHA 2020
  • DSS N/A
  • Fundamental
  • Price
  • ATHA $0.42
  • DSS $0.90
  • Analyst Decision
  • ATHA Buy
  • DSS
  • Analyst Count
  • ATHA 4
  • DSS 0
  • Target Price
  • ATHA $11.25
  • DSS N/A
  • AVG Volume (30 Days)
  • ATHA 239.8K
  • DSS 189.3K
  • Earning Date
  • ATHA 07-31-2025
  • DSS 08-12-2025
  • Dividend Yield
  • ATHA N/A
  • DSS N/A
  • EPS Growth
  • ATHA N/A
  • DSS N/A
  • EPS
  • ATHA N/A
  • DSS N/A
  • Revenue
  • ATHA N/A
  • DSS $20,180,000.00
  • Revenue This Year
  • ATHA N/A
  • DSS N/A
  • Revenue Next Year
  • ATHA N/A
  • DSS N/A
  • P/E Ratio
  • ATHA N/A
  • DSS N/A
  • Revenue Growth
  • ATHA N/A
  • DSS 12.88
  • 52 Week Low
  • ATHA $0.22
  • DSS $0.72
  • 52 Week High
  • ATHA $3.67
  • DSS $1.64
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 73.73
  • DSS 49.74
  • Support Level
  • ATHA $0.29
  • DSS $0.88
  • Resistance Level
  • ATHA $0.32
  • DSS $0.92
  • Average True Range (ATR)
  • ATHA 0.03
  • DSS 0.07
  • MACD
  • ATHA 0.01
  • DSS -0.00
  • Stochastic Oscillator
  • ATHA 78.16
  • DSS 45.87

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

About DSS DSS Inc.

DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.

Share on Social Networks: